2Genant HK, Cooper C, Poor G, et al. Interim report and recom- mendations of the World Health Organization task-force for osteopo- rosis[J]. Osteoporos In, 1999, 10(4) : 259-264.
3D' Amelio P, Spertino E, Martino F, et al. Prevalence of Postm- enopausal Osteoporosis in Italy and Validation of Decision Rules for Referring Women for Bone Densitometry [ J ]. Calcif Tissue Int, 2013, 92(5) : 437-443.
4Gleason LJ, Menzies IB, Mendelson DA, et al. Diagnosis and treatment of osteoporosis in high-risk patients prior to hip fracture [ J ] Geriatr Orthop Surg Rehabil, 2012, 3 (2) : 79-83.
5McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday[J]. Am J Med, 2013, 126(1): 13-20.
6李翠妮.抗骨质疏松药物的研究进展[J].医药前沿,2012,2(27):51-52.
7Koivukangas A, Tuukkanen J, Hannuniemi R, et al. Effects of long-term administration of clodronate on growing rat bone [ J]. Calcif Tissue Int, 2001, 69(6): 350-355.
8Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [ J ]. N Engl J Med, 2007, 356(18): 1809-1822.
9Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphos- phonate treatment for osteoporosis--for whom and for how long[ J ]. N Engl J Med, 2012, 366(22) : 2051-2053.
10Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteopo- rosis--where do we go from here[J] N Engl J Med, 2012, 366(22) : 2048-2051.
